Emese Zsiros, MD, PhD, FACOG | Authors


Rationalizing the Use of Pembrolizumab/Bevacizumab in Women With Recurrent Ovarian Cancer

December 04, 2019

Emese Zsiros, MD, PhD, FACOG, assistant professor of oncology, Department of Gynecologic Oncology, Center for Immunotherapy, Roswell Park Comprehensive Cancer Center explains the rationale for the a phase II study, which combined pembrolizumab with bevacizumab in patients with recurrent ovarian cancer. Zsiros presented data on the study in early 2019 at the SGO Annual Meeting.